Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02732 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Meng Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Protein arginine methyltransferase 5 (PRMT5), which catalyzes the symmetric dimethylation of arginine residues on target proteins, plays a critical role in gene expression regulation, RNA processing, and signal transduction. Aberrant PRMT5 activity has been implicated in cancers and other diseases, making it a potential therapeutic target. Here, we report the discovery of a methylthioadenosine (MTA) cooperative PRMT5 inhibitor. Compound 20 exhibited strong antiproliferation activity in multiple MTAP-deleted cancer cell lines, excellent selectivity over MTAP wild-type cell lines, as well as satisfactory oral pharmacokinetic properties over various preclinical species. Notably, compound 20 demonstrated a dose-dependent reduction of symmetric dimethylarginine (SDMA) expression in the LU99 cell line and robust in vivo antitumor activity in the LU99 subcutaneous model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.
- Insilico Medicine AI Ltd, Masdar City, Abu Dhabi 145748, UAE.
- Insilico Medicine Hong Kong Ltd, Hong Kong Science and Technology Park, Kowloon 999077, Hong Kong SAR, China.
ORCID-Profile: Xiao Ding, Alex Aliper, Feng Ren, Hongfu Lu, Alex Zhavoronkov
Zitieren
APA
Zhang, M., Ding, X., Cao, Z., Yang, Y., Ding, X., Cai, X., Zhang, M., Aliper, A., Ren, F., Lu, H., & Zhavoronkov, A. (2025). Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02732
Vancouver
Zhang M, Ding X, Cao Z, Yang Y, Ding X, Cai X, et al. Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02732
BibTeX
@article{Zhang2025,
author = {Zhang, Meng and Ding, Xiaoyu and Cao, Zhongying and Yang, Yilin and Ding, Xiao and Cai, Xin and Zhang, Man and Aliper, Alex and Ren, Feng and Lu, Hongfu and Zhavoronkov, Alex},
title = {Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02732}
}
EUVIMED